Stereotaxis Completes First US MAGiC Ablation Procedures for Complex Heart Disease
Event summary
- Stereotaxis completed first US procedures using its MAGiC ablation catheter, approved by FDA in April 2026 for complex congenital heart disease patients.
- Dr. Nathan McConkey performed the inaugural procedure at Oregon Health & Science University on a patient with atrial flutter unresponsive to manual ablation methods.
- MAGiC catheter enables novel access routes (e.g., basilic vein) and superior stability for challenging anatomies.
- Baptist Health Lexington's Dr. Gery Tomassoni highlights MAGiC as a long-awaited advancement for complex arrhythmia cases.
The big picture
Stereotaxis' MAGiC catheter represents a strategic breakthrough in treating arrhythmias for patients with congenital heart defects, a historically underserved population. The technology addresses critical limitations of manual ablation methods, potentially expanding the addressable market for robotic magnetic navigation systems. This approval positions Stereotaxis to compete more aggressively with traditional electrophysiology players in complex cardiac cases.
What we're watching
- Adoption Pace
- How quickly MAGiC will be integrated into standard care for congenital heart disease patients across US hospitals.
- Clinical Outcomes
- Whether MAGiC's precision translates to sustained reduction in arrhythmia recurrence rates compared to manual methods.
- Reimbursement Dynamics
- The timeline for CMS and private payers to establish reimbursement codes for MAGiC procedures.